Since an increase in telehealth visits since the COVID-19 pandemic, assessing for tardive dyskinesia (TD) has been a challenge, but evaluation can be successful based on best practices that are described in this article. It is important for psychiatric nurses to educate patients and caregivers on the potential risks of antipsychotic-induced movement disorders including TD. Researchers of this article also note that nurses should be attentive that every patient taking antipsychotics should be monitored for the potential development of TD. After a TD diagnosis, nurses can educate patients about safe and effective treatments that are available and approved by the Food and Drug Administration.
Reference: Warren B, Vanderhoef D, Johnson J. VMAT2 Inhibitors for the Treatment of Tardive Dyskinesia. Issues Ment Health Nurs. 2022;43(1):22-31. doi:10.1080/01612840.2021.1948643